Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Sarepta Reports Second Death of Patient Using Its Gene Therapy

Sarepta Therapeutics Inc. said a second patient has died of acute liver failure after being treated with its gene therapy for a rare muscle disorder.

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 15, 2025

Sarepta reports second patient death after treatment with Duchenne gene therapy

The company said it had paused shipments of the therapy, called Elevidys, for patients who can no longer walk.

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 15, 2025-

Sarepta pauses Duchenne gene therapy for non-ambulatory individuals after second death due to acute liver failure

CureDuchenne is sad to share that another person has passed away due to acute liver failure after treatment with Elevidys, Sarepta’s micro-dystrophin gene therapy.  Our hearts go out to the family and friends of this individual at this difficult time.   While regulators and experts are reviewing the data and looking at possible safety enhancements including additional immunosuppression, Sarepta will be pausing Elevidys treatments for non-ambulat…

Sarepta Therapeutics (Nasdaq:SRPT) - Stock Price, News & Analysis - Simply Wall St

Research Sarepta Therapeutics' (Nasdaq:SRPT) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more.